{
    "nctId": "NCT01750164",
    "briefTitle": "Patient Derived Breast Cancer Xenografts",
    "officialTitle": "Patient Derived Breast Cancer Xenografts",
    "overallStatus": "TERMINATED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Successful Engraftment",
    "eligibilityCriteria": "* Women \\> age 18. with a history of ER+. HER-2 negative breast cancer previously treated with adjuvant anti-estrogen therapy (tamoxifen or aromatase inhibitor? for at least 1 year after surgical resection of primary tumor.\n* ER+ status requires positive staining in \\> 10% of malignant cells in biopsy specimen.\n* HER-2 Negative status requires Immunohistochemistry 0-1+, or with a FISH ratio of \\< 2.0 if IHC is 2+ or if IHC has not been done.\n* Patient must have: A. newly diagnosed recurrent, locally advanced or metastatic breast cancer. B. existing advanced or metastatic breast cancer.\n* Patient must be having clinically indicated: A. diagnostic tumor biopsy via core-or needle incision or B. surgical removal of tumor or C. collection of pleural or ascetic fluid in order to obtain fresh tumor tissue for research (transplant into mice).\n* For subjects having a diagnostic tumor biopsy, excess fresh tumor tissue must be available from the biopsy for research for immediate transplantation into mice.\n* For subjects having a surgical resection of the primary tumor, the tumor must have a clinical size of 1 cm or greater, and and excess fresh tumor tissue must be available from the surgical specimen for research for immediate transplantation into mice.\n* Ability to give signed informed consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}